GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Dermata Therapeutics
Dermata Therapeutics is a biotech company focused on treating skin diseases. Its stock price is highly volatile and driven by news about the progress of its drug clinical trials.
Share prices of companies in the market segment - Pharma skin
Dermata Therapeutics is a pharmaceutical company developing treatments for skin conditions such as acne, rosacea, and hyperhidrosis. We've categorized it as a "Pharma: Skin" company. The chart below shows how investors value companies in the stable and large dermatology sector.
Broad Market Index - GURU.Markets
Dermata Therapeutics is a dermatology company developing treatments for acne, rosacea, and other skin conditions. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the pharmaceutical sector.
Change in the price of a company, segment, and market as a whole per day
DRMA - Daily change in the company's share price Dermata Therapeutics
Dermata Therapeutics, Inc.'s daily stock price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its skin treatments.
Daily change in the price of a set of shares in a market segment - Pharma skin
Dermata Therapeutics develops drugs to treat skin conditions using its platform to improve drug delivery. Dermatology is a competitive segment of the pharmaceutical industry. The chart below shows the average volatility in this niche, allowing you to compare DRMA stock performance with other companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Dermata Therapeutics is a pharmaceutical company focused on dermatology. Its shares are driven by successful drug commercialization and clinical trial results. The dynamics of this niche healthcare segment are part of a larger and more diverse picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Dermata Therapeutics
For Dermata Therapeutics, year-over-year performance is a reflection of its drug development for treating skin conditions. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead acne treatment candidate, which uses a unique sponge technology, could be a breakthrough in dermatology.
Annual dynamics of market capitalization of the market segment - Pharma skin
Dermata, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its skin treatments. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dermata Therapeutics is a biotech company whose value is based on the hope of developing a new skin treatment. Its year-over-year performance relative to the market isn't a reflection of business processes, but a speculative bet on clinical trial success. The chart is a series of sharp movements driven by news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Dermata Therapeutics
Dermata is a late-stage dermatology company. Its monthly performance is entirely dependent on the results of its key clinical trials. Data from its acne and rosacea treatments is the key event shaping expectations.
Monthly dynamics of market capitalization of the market segment - Pharma skin
Developing new treatments for skin diseases is a key area of pharmaceuticals. The dynamics of this biotech sector, shown in the graph, reflect the risks and potential of clinical trials. Companies like Dermata Therapeutics are pursuing programs in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dermata Therapeutics is an early-stage biotech company. Its shares are steeped in lab data and investor expectations about science. Their value can fluctuate wildly, ignoring macroeconomic events and overall market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Dermata Therapeutics
Dermata Therapeutics, a biotech company focused on dermatology, relies on clinical success. Its weekly stock price reflects development updates on its drug candidates, which could offer new solutions for treating skin diseases.
Weekly dynamics of market capitalization of the market segment - Pharma skin
Dermata Therapeutics develops drugs to treat skin conditions such as acne and rosacea. Its strategy involves improving existing drugs with a new delivery system. The chart below shows how investors view this approach and how it relates to the dermatology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Dermata Therapeutics develops drugs to treat skin diseases. Its strategy involves improving existing medications. The chart shows how investors view this approach and how it compares to the broader market.
Market capitalization of the company, segment and market as a whole
DRMA - Market capitalization of the company Dermata Therapeutics
Dermata Therapeutics' market capitalization chart reflects investor sentiment on its skin treatments. Its dynamics reflect the market's faith in its approach, which combines established drugs with new delivery technologies. Its low valuation reflects the potential of its programs for treating acne, rosacea, and other conditions.
DRMA - Share of the company's market capitalization Dermata Therapeutics within the market segment - Pharma skin
Dermata Therapeutics develops drugs to treat skin diseases. Its small market share in the pharmaceutical sector reflects its research-based nature. Its market cap is based on its Spongilla technology, which uses microneedles made from freshwater sponges to deliver drugs into the skin.
Market capitalization of the market segment - Pharma skin
Below is a graph showing the total value of the entire pharmaceutical sector focused on skincare. For Dermata, which operates in this field, this line is a map of the beauty and wellness industry. Its dynamics reflect both the demand for aesthetic procedures and the need to treat common skin conditions like acne.
Market capitalization of all companies included in a broad market index - GURU.Markets
Dermata Therapeutics develops drugs to treat skin conditions such as acne and rosacea. Its market capitalization is a measure of its dermatology portfolio. Overall, this represents the share of the company's business treating common skin conditions.
Book value capitalization of the company, segment and market as a whole
DRMA - Book value capitalization of the company Dermata Therapeutics
Dermata Therapeutics is a dermatology company developing drugs to treat acne, rosacea, and other skin conditions. Its book value represents its financial resources for conducting clinical trials. How has this vital asset changed? The chart below shows.
DRMA - Share of the company's book capitalization Dermata Therapeutics within the market segment - Pharma skin
Dermata Therapeutics is a biopharmaceutical company focused on dermatology. Its scientific research requires a physical base: a laboratory for the creation and testing of new drugs for the treatment of skin diseases. The chart shows the company's share of the physical R&D infrastructure in this specific biopharma segment.
Market segment balance sheet capitalization - Pharma skin
Dermata Therapeutics is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Dermata focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Dermata's assets are not factories, but capital invested in clinical trials of its drug candidates for the treatment of acne, rosacea, and other skin conditions, using unique delivery technologies. These assets represent its financial resources for these developments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Dermata Therapeutics
Dermata Therapeutics is a dermatology company. Its market value is based on its portfolio of skin treatments. Investors evaluate its ability to successfully commercialize these products and establish a market niche.
Market to book capitalization ratio in a market segment - Pharma skin
Dermata Therapeutics is a pharmaceutical company specializing in the treatment of skin diseases. Its valuation on this chart will reflect both the sales of its existing products and the potential of its clinical-stage development pipeline.
Market to book capitalization ratio for the market as a whole
Dermata Therapeutics is a dermatology company developing drugs to treat skin conditions. Its valuation depends on the success of clinical trials. This chart shows how investors value specialty pharmaceutical companies operating in large consumer markets.
Debts of the company, segment and market as a whole
DRMA - Company debts Dermata Therapeutics
Dermata, a clinical-stage biopharmaceutical company developing drugs to treat skin diseases, is entirely dependent on external funding. This chart shows its financial struggle to survive and its efforts to bring its products through costly clinical trials.
Market segment debts - Pharma skin
Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for skin conditions such as acne and rosacea. This chart shows how the company funds its clinical trials, aiming to offer new treatments for the widespread yet competitive dermatology markets.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Dermata Therapeutics
Dermata Therapeutics develops drugs to treat skin diseases using its unique drug delivery technology. Clinical trials in dermatology are a lengthy and expensive process. This chart shows how the company uses debt capital to fund its R&D programs and advance its products toward commercialization.
Market segment debt to market segment book capitalization - Pharma skin
Dermata Therapeutics is a pharmaceutical company developing drugs to treat skin diseases. Dermatology is a competitive market. This chart shows how the company finances its clinical trials. It compares its debt load to the market capitalization of the entire pharmaceutical sector, reflecting its financial risks.
Debt to book value of all companies in the market
Dermata Therapeutics develops drugs to treat skin diseases. Dermatology is a competitive market, and launching a new product requires significant investment. How heavily does the company rely on debt to achieve commercialization? This chart of total debt in the market provides context for assessing its financial strength.
P/E of the company, segment and market as a whole
P/E - Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for skin diseases. This chart shows how investors value its pipeline. The valuation is volatile and depends on news about the progress of clinical trials.
P/E of the market segment - Pharma skin
Dermata Therapeutics is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. This chart illustrates the average valuation in the dermatology pharmaceutical sector, which has a large market but is also highly competitive.
P/E of the market as a whole
Dermata Therapeutics is a clinical-stage biopharmaceutical company developing treatments for skin conditions such as acne, rosacea, and psoriasis. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether DRMA's valuation is based on confidence in its product portfolio or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Dermata Therapeutics
Dermata Therapeutics is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. This chart shows how investors assess the likelihood of success of its clinical programs and the commercial potential of new treatments in the vast dermatology market.
%20P%2FE%20Dermata%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Dermata-Therapeutics&v=1772630125966 "Chart of the company's future (projected) P/E Dermata Therapeutics")
Future (projected) P/E of the market segment - Pharma skin
Dermata Therapeutics develops treatments for skin conditions such as acne, rosacea, and psoriasis using its proprietary delivery technologies. The chart compares Dermata's future profitability expectations with those of the sector, helping to understand the market's confidence in the effectiveness of its approach to treating common skin conditions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-skin&v=1772630125977 "Future (projected) P/E graph of the market segment - Pharma skin")
Future (projected) P/E of the market as a whole
Dermata Therapeutics is a pharmaceutical company developing treatments for skin conditions such as acne and rosacea. The dermatology market is vast and competitive. This market sentiment chart helps understand how investors view the prospects of new players in this saturated field.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772630125996 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs to treat skin conditions such as acne and rosacea. Financial metrics reflect clinical trial expenses. This chart shows investments in developing new therapeutic options for common dermatological conditions.
Profit of companies in the market segment - Pharma skin
Dermata Therapeutics is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions using innovative mechanisms of action. This chart illustrates the overall profitability of the dermatology pharmaceutical sector, where even small improvements in efficacy or safety can capture significant market share.
Overall market profit
Dermata Therapeutics is a pharmaceutical company specializing in the treatment of skin diseases. Demand for its products is driven by medical needs and patients' desire to improve their quality of life. This market is less cyclical than other consumer sectors, and its dynamics are weakly correlated with overall corporate profitability, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Dermata Therapeutics
Dermata Therapeutics is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. Future revenue depends on clinical trial results. This chart shows analysts' speculative expectations for its product portfolio.
%20profit%20of%20the%20company%20Dermata%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Dermata-Therapeutics&v=1772630126147 "Graph of future (projected) profit of the company Dermata Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma skin
Dermata Therapeutics is a dermatology company developing medications for the treatment of acne, rosacea, and other skin conditions. Its technology enables the delivery of active ingredients deep into the skin. This chart shows revenue projections for the dermatology pharmaceutical segment, providing context for evaluating Dermata's product line.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-skin&v=1772630126171 "Graph of future (predicted) profits of companies in a market segment - Pharma skin")
Future (predicted) profit of the market as a whole
Dermata Therapeutics is a biopharmaceutical company specializing in skin treatments. Its revenue depends on the successful commercialization of its products. The overall economic situation, reflected in this chart, affects the ability of patients and the healthcare system to pay, which impacts sales.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772630126205 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Dermata Therapeutics
Dermata Therapeutics is a clinical-stage dermatology company with no revenue. This chart reflects investor valuations of its pipeline of candidates for the treatment of acne, rosacea, and other skin conditions. The company's performance is dependent on trial news.
P/S market segment - Pharma skin
Dermata Therapeutics is a clinical-stage biopharmaceutical company developing treatments for skin conditions. Their technology enables the delivery of active ingredients into the deep layers of the skin, improving the effectiveness of treatments for acne, rosacea, and psoriasis. This chart shows the average revenue estimate for the sector, which helps assess the potential of their platform.
P/S of the market as a whole
Dermata Therapeutics is a pharmaceutical company specializing in the development of treatments for skin conditions such as acne and rosacea. This chart, which displays average revenue estimates, helps us understand that the valuation of such companies depends on the size of their target market and the success of their clinical trials.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of skin conditions such as acne, rosacea, and hyperhidrosis. Its revenue valuation is important to the company. It reflects investor expectations for the success of its products in clinical trials and their commercial potential in the large and competitive dermatology market.
%20P%2FS%20Dermata%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Dermata-Therapeutics&v=1772630126337 "The graph of the company's future (projected) P/S Dermata Therapeutics")
Future (projected) P/S of the market segment - Pharma skin
Dermata Therapeutics develops drugs to treat skin conditions. Its lead candidate is designed to treat acne, rosacea, and other conditions. This chart compares the company's estimated future sales with expectations for the dermatology pharmaceutical market. It shows how investors view the potential of its unique drug delivery technology.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20skin&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-skin&v=1772630126407 "Future (projected) P/S market segment graph - Pharma skin")
Future (projected) P/S of the market as a whole
Dermata Therapeutics develops treatments for skin diseases using its Spongilla technology, which improves the delivery of active ingredients. The company's future depends on the success of this platform. This market outlook chart reflects investor interest in innovative drug delivery methods in dermatology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772630126468 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Dermata Therapeutics
This metric for Dermata Therapeutics reflects the financial activity of the company, which develops drugs to treat skin conditions such as acne and rosacea. While in clinical trials, the company may not have stable sales revenue.
Sales of companies in the market segment - Pharma skin
Dermata Therapeutics is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. It currently has no sales revenue. Its future revenue is entirely dependent on the success of its drug candidates in obtaining regulatory approval and reaching the market.
Overall market sales
Dermata Therapeutics is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. Demand for its products will be determined by efficacy and safety. This trend in overall consumer activity may impact the aesthetic medicine market, but demand for the treatment of serious conditions is more stable.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Dermata Therapeutics
Dermata Therapeutics is a dermatology company developing drugs to treat skin conditions such as acne, rosacea, and psoriasis. Its future revenue depends on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its product portfolio in the large and competitive dermatology market.
%20sales%20of%20the%20company%20Dermata%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Dermata-Therapeutics&v=1772630126633 "Schedule of future (projected) sales of the company Dermata Therapeutics")
Future (projected) sales of companies in the market segment - Pharma skin
Dermata Therapeutics develops medications to treat skin conditions such as acne and rosacea. This chart shows the sales forecast for the entire dermatology market. Is demand for innovative therapies for common but difficult-to-treat skin conditions growing? This reflects the overall potential of this segment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-skin&v=1772630126669 "Schedule of future (projected) sales of companies in the market segment - Pharma skin")
Future (projected) sales of the market as a whole
Dermata Therapeutics is a pharmaceutical company specializing in the development of treatments for skin diseases. Demand for its products is driven by medical needs, but it can be influenced by the economic situation, especially when it comes to cosmetic conditions such as acne. This dynamic may indirectly influence patients' willingness to pay for treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772630126672 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Dermata Therapeutics
Dermata Therapeutics is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. This chart shows its financial trajectory. Profitability depends on successful clinical trial results and the ability of its products to offer superior solutions compared to existing products.
Market segment marginality - Pharma skin
Dermata Therapeutics, Inc. is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. This chart reflects its financial position, with profitability being a future goal dependent on the success of its candidates in clinical trials.
Market marginality as a whole
Dermata Therapeutics is a clinical-stage dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. Its success depends on research results. This gross profitability chart reflects the investment climate that influences the funding of biotech companies operating in a competitive market.
Employees in the company, segment and market as a whole
Number of employees in the company Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biotech company developing drugs to treat skin conditions such as acne and rosacea. Its small, largely virtual team manages clinical trials. This chart shows a lean structure that outsources most of its R&D to leverage capital.
Share of the company's employees Dermata Therapeutics within the market segment - Pharma skin
Dermata Therapeutics is a dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. Its activities are focused on clinical trials. This graph shows the company's market share, which is an indicator of the scale of its clinical programs and the size of its research team.
Number of employees in the market segment - Pharma skin
Dermata Therapeutics develops treatments for skin conditions using proprietary technology to improve the delivery of active ingredients. The chart below shows the company's presence in the skin pharmaceuticals sector. The company's goal is to create more effective and convenient treatments for acne, rosacea, and other common conditions.
Number of employees in the market as a whole
Dermata Therapeutics is a biopharmaceutical company focused on treating skin diseases. Its growth depends on clinical trial results and regulatory approvals. This chart shows the overall picture, and Dermata is an example of a biotech company where job creation is directly tied to progress in solving specific medical problems.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Dermata Therapeutics (DRMA)
Dermata Therapeutics is a biotech company focused on treating skin conditions (acne, rosacea) using its drug delivery platform. This chart shows how the market values their R&D. It reflects the market value per employee, which is a measure of the value of their IP in dermatology.
%20of%20the%20company%20Dermata%20Therapeutics%20(DRMA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Dermata-Therapeutics-DRMA&v=1772630126891 "Chart of market capitalization per employee (in thousands of dollars) of the company Dermata Therapeutics (DRMA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma skin
Dermata Therapeutics (DRMA) is a dermatology company developing drugs for the treatment of acne, rosacea, and other skin conditions. In this field, this metric reflects the potential of their portfolio. A high employee score may indicate that the company has discovered a unique molecule or mechanism of action that could become a new standard in the treatment of common skin conditions.
%20by%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-skin&v=1772630126922 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma skin")
Market capitalization per employee (in thousands of dollars) for the overall market
Dermata Therapeutics is a dermatology company developing treatments for acne and other skin conditions. Its valuation is based on the potential of its products. The chart shows a high valuation per employee, as the market sees strong demand for new and effective treatments for common skin problems.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772630126958 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Dermata Therapeutics (DRMA)
Dermata Therapeutics is a clinical-stage biotech company developing drugs for the treatment of skin conditions (acne, rosacea). This chart reflects the R&D workload. A negative R&D workload (loss per employee) is typical for biotech companies, reflecting the amount of capital invested in each scientist to conduct trials.
%20Chart%20Dermata%20Therapeutics%20(DRMA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Dermata-Therapeutics-DRMA&v=1772630126982 "Company Profit Per Employee (in thousands of dollars) Chart Dermata Therapeutics (DRMA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma skin
Dermata Therapeutics, Inc. is a biopharmaceutical company focused on treating skin diseases. In dermatology, the company's return per employee depends on the potential of its drugs for a broader market. The graph shows the financial return per team, which is an indicator of the commercial viability of its developments compared to competitors.
%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-skin&v=1772630126990 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma skin")
Profit per employee (in thousands of dollars) for the market as a whole
Dermata Therapeutics is a biotech company focused on dermatology. They develop drugs for the treatment of acne and rosacea using their delivery platform. This is an R&D business. This graph, showing the average market efficiency, provides context for evaluating the biotech model: all value is created through intellectual labor.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772630127031 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Dermata Therapeutics (DRMA)
Dermata Therapeutics is a clinical-stage dermatology company. Zero revenue per employee is the norm at this stage. The graph illustrates the potential: a successful drug for acne or other common skin conditions could have a huge market and lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Dermata-Therapeutics-DRMA&v=1772630127038 "Sales chart per company employee Dermata Therapeutics (DRMA)")
Sales per employee in the market segment - Pharma skin
Dermata Therapeutics (DRMA) is a clinical-stage biotech focused on dermatology. They are developing drugs (based on the Spongilla technology) for the treatment of acne and rosacea. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of Dermata's R&D staffing costs.
Sales per employee for the market as a whole
Dermata Therapeutics (DRMA) is a biotech company developing drugs to treat skin conditions (acne, rosacea). Currently, their business is focused on R&D. This chart reflects their clinical stage: the company invests in research and has no commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Dermata Therapeutics (DRMA)
Dermata (DRMA) is a dermatology company developing treatments for acne and rosacea. This chart shows the number of short positions. Short positions reflect a bet that the company's drugs will fail to prove effective in trials in the crowded acne market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Dermata-Therapeutics-DRMA&v=1772630127186 "Short Shares Chart for the Company Dermata Therapeutics (DRMA)")
Shares shorted by market segment - Pharma skin
Dermata Therapeutics (DRMA) is a dermatology company developing drugs for the treatment of acne, rosacea, and psoriasis using its sponge-based delivery technology. This chart aggregates short positions in the biotech (dermatology) sector. It reflects investor skepticism regarding the risks of clinical trials in this competitive field.
Shares shorted by the overall market
Dermata Therapeutics is a clinical-stage biotech developing drugs to treat acne and other skin conditions. This chart measures overall fear. When investors are pessimistic, they are unprepared for the binary risks of clinical trials. They sell off DRMA shares, fearing the company will run out of cash before it can prove the effectiveness of its developments.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Dermata Therapeutics (DRMA)
This oscillator for Dermata Therapeutics shows bets on innovation in dermatology. The company is developing drugs to treat acne and rosacea. "Overbought" levels (above 70) arise in anticipation of clinical trial data. A study failure or an FDA request for additional testing (as has happened before) immediately sends the indicator into "oversold" territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Dermata-Therapeutics-DRMA&v=1772630127237 "RSI 14 indicator chart for the company's stock Dermata Therapeutics (DRMA)")
RSI 14 Market Segment - Pharma skin
Dermata Therapeutics is a biopharmaceutical company specializing in dermatology. Their Spongilla (freshwater sponge) technology is used to deliver drugs for the treatment of acne and psoriasis. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry as a whole.
RSI 14 for the overall market
Dermata Therapeutics (DRMA) is a biotech company specializing in dermatology. Like many companies in clinical development, its stock is volatile and dependent on sector sentiment. This chart shows the overall market temperature, helping to understand when investors are risk-seeking (euphoria) or, conversely, panic-averse (oversold), which directly impacts capital availability for DRMA.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DRMA (Dermata Therapeutics)
Dermata Therapeutics is a biotech company focused on dermatology. Its platform (DMT310) uses freshwater sponges to deliver drugs to the skin (for the treatment of acne and psoriasis). This chart shows the speculative average 12-month price target from analysts based on their confidence in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DRMA-Dermata-Therapeutics&v=1772630127279 "A chart showing analyst consensus forecasts for the expected stock price. DRMA (Dermata Therapeutics)")
The difference between the consensus estimate and the actual stock price DRMA (Dermata Therapeutics)
Dermata is a biotech company developing drugs to treat skin conditions (acne, rosacea) using its "sponge" delivery technology. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in this R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DRMA-Dermata-Therapeutics&v=1772630127352 "A chart showing the difference between the consensus forecast and the actual stock price. DRMA (Dermata Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma skin
Dermata is an R&D biotech company developing drugs (based on its "sponge" delivery technology) for the treatment of severe skin conditions such as acne and rosacea. This chart reflects analysts' overall expectations across the skin pharma sector. It shows whether experts believe in the success of new R&D approaches in dermatology.
Analysts' consensus forecast for the overall market share price
Dermata Therapeutics is a biotech company specializing in developing drugs to treat skin conditions such as acne. This chart shows the overall risk appetite in the market. For DRMA, a high-risk clinical-stage company, overall market optimism (as shown by the rising chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Dermata Therapeutics
Dermata is a biotech company for acne. Their signature feature is mechanical (rather than chemical) delivery: they use a micro-sponge to massage the medication (DMT310) deep into the skin to treat acne and rosacea. This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma skin
Dermata Therapeutics is a dermatology company targeting large markets: acne, rosacea, and psoriasis. They strive to improve existing treatments, making them more effective. This chart compares their composite index to the sector, showing how their approach to common skin conditions compares to their competitors.
The AKIM Index for the overall market
Dermata Therapeutics is a biotech company focused on dermatology. It develops treatments for acne, rosacea, and hyperhidrosis using its Spongilla technology. This chart, which reflects the market average, provides a macro backdrop. It helps assess how DRMA, a niche dermatology developer, stacks up against overall economic trends.
